PT1844337E - Compostos ligantes, compostos imunogénicos e peptidomiméticos - Google Patents

Compostos ligantes, compostos imunogénicos e peptidomiméticos Download PDF

Info

Publication number
PT1844337E
PT1844337E PT67016063T PT06701606T PT1844337E PT 1844337 E PT1844337 E PT 1844337E PT 67016063 T PT67016063 T PT 67016063T PT 06701606 T PT06701606 T PT 06701606T PT 1844337 E PT1844337 E PT 1844337E
Authority
PT
Portugal
Prior art keywords
compounds
peptidomimetics
immunogenic
binding
binding compounds
Prior art date
Application number
PT67016063T
Other languages
English (en)
Inventor
Jelle Wouter Slootstra
Wouter Cornelis Puijk
Evert Van Dijk
Peter Timmerman
Robbert Hans Meloen
Original Assignee
Pepscan Systems Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pepscan Systems Bv filed Critical Pepscan Systems Bv
Publication of PT1844337E publication Critical patent/PT1844337E/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806Determination of free amino acids
    • G01N33/6812Assays for specific amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5409IL-5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
PT67016063T 2005-01-24 2006-01-24 Compostos ligantes, compostos imunogénicos e peptidomiméticos PT1844337E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05075174 2005-01-24
EP05077896 2005-12-16

Publications (1)

Publication Number Publication Date
PT1844337E true PT1844337E (pt) 2014-04-03

Family

ID=36168379

Family Applications (1)

Application Number Title Priority Date Filing Date
PT67016063T PT1844337E (pt) 2005-01-24 2006-01-24 Compostos ligantes, compostos imunogénicos e peptidomiméticos

Country Status (13)

Country Link
US (1) US7863239B2 (pt)
EP (1) EP1844337B1 (pt)
JP (1) JP5372380B2 (pt)
AU (1) AU2006206848B2 (pt)
CA (1) CA2595902C (pt)
CY (1) CY1114441T1 (pt)
DK (1) DK1844337T3 (pt)
ES (1) ES2428869T3 (pt)
NZ (1) NZ560504A (pt)
PL (1) PL1844337T3 (pt)
PT (1) PT1844337E (pt)
SI (1) SI1844337T1 (pt)
WO (1) WO2006078161A1 (pt)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2518865T3 (es) * 2004-04-13 2014-11-05 St Vincent's Hospital Sydney Limited Agente de inhibición de MIC-1
US7598356B2 (en) 2004-07-08 2009-10-06 Board of Regents of the University of Nebraska by and on behalf of the University of Nebraska Medical Center Method for purifying a protein of the cystine-knot superfamily
DE102005022047A1 (de) 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
EP2052253A2 (en) * 2006-07-26 2009-04-29 Pepscan Systems B.V. Immunogenic compounds and protein mimics
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2686827C (en) 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
WO2008104000A2 (en) 2007-02-23 2008-08-28 Aileron Therapeutics, Inc. Triazole macrocycle systems
ES2610531T3 (es) 2007-03-28 2017-04-28 President And Fellows Of Harvard College Polipéptidos cosidos
EP2653544A1 (en) * 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and compositions
JPWO2009107771A1 (ja) * 2008-02-27 2011-08-04 国立大学法人大阪大学 金−酸化鉄複合ナノ粒子を用いたペプチドの合成方法
CA2744088A1 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
GB0914110D0 (en) * 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
US20130072439A1 (en) 2009-09-22 2013-03-21 Huw M. Nash Peptidomimetic macrocycles
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
GB201013980D0 (en) 2010-08-20 2010-10-06 Ecole Polytech Bicyclic uPA inhibitors
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
EP3434691A1 (en) 2010-12-01 2019-01-30 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US9029332B2 (en) 2010-12-15 2015-05-12 The Research Foundation For The State University Of New York Cross-linked peptides and proteins, methods of making same, and uses thereof
PT2726101T (pt) 2011-06-30 2018-11-21 Genzyme Corp Inibidores da ativação de células t
US20130101664A1 (en) 2011-08-18 2013-04-25 Donald W. Kufe Muc1 ligand traps for use in treating cancers
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
CN103906865B (zh) * 2011-10-07 2017-12-08 拜斯科医疗有限公司 结构化多肽特异性的调控
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
US20140357577A1 (en) * 2011-12-19 2014-12-04 Janssen R&D Limited HIV Membrane Fusion Inhibitors
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
MX362492B (es) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos.
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス,インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2013172954A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
US9556229B2 (en) 2012-05-18 2017-01-31 The Regents Of The University Of California Modification of peptides using a bis(thioether)arylbridge approach
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014116789A1 (en) * 2013-01-25 2014-07-31 Thymon, Llc Immunogenic and prophylactic compositions, methods of making same, and method for treating and preventing tnf-mediated disease and hiv-1 infection
KR101759687B1 (ko) 2013-01-25 2017-07-19 타이몬, 엘엘씨 순환하는 생물활성 가용성 tnf의 선택적 감소를 위한 조성물 및 tnf-매개 질환의 치료 방법
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
EP2767549A1 (en) 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
GB201306623D0 (en) * 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
BR112015032554A8 (pt) * 2013-06-25 2018-01-23 Sepia Pesquisa E Desenvolvimento moduladores do receptor de bradicinina e seu uso
CA2927554C (en) 2013-10-28 2022-11-29 Bicycle Therapeutics Limited Novel polypeptides
WO2015166036A1 (en) * 2014-05-02 2015-11-05 Morphosys Ag Peptide libraries
DK3154561T3 (da) 2014-06-12 2019-10-07 Ra Pharmaceuticals Inc Modulering af komplementaktivitet
AP2016009663A0 (en) 2014-07-30 2016-12-31 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
DK3215518T3 (da) 2014-10-29 2021-05-25 Bicyclerd Ltd Bicykliske peptidligander, der er specifikke for mt1-mmp
TN2017000113A1 (en) 2014-10-31 2018-07-04 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
LT3250230T (lt) 2015-01-28 2021-12-27 Ra Pharmaceuticals, Inc. Komplemento aktyvumo moduliatoriai
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US11578110B2 (en) 2015-08-25 2023-02-14 Histide Ag Compounds for inducing tissue formation and uses thereof
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. Mcl−1のモジュレーターとしてのペプチド模倣大環状分子
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
ES2900480T3 (es) * 2015-09-17 2022-03-17 Histide Ag Asociaciones farmacéuticas de agonistas de receptores de factor de crecimiento e inhibidores de proteínas de adhesión para la conversión de células neoplásicas en células no neoplásicas y usos de las mismas
CN109715190A (zh) * 2015-09-17 2019-05-03 伊斯迪德股份公司 将赘生性细胞转化成非赘生性细胞的生长因子受体激动剂和黏附蛋白抑制剂的药物缔合物及其用途
WO2017046229A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
SG11201804721SA (en) 2015-12-16 2018-07-30 Ra Pharmaceuticals Inc Modulators of complement activity
GB201600903D0 (en) 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Peptide derivaties
GB201600911D0 (en) 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Stabilized peptide derivatives
SG11201807279QA (en) 2016-03-31 2018-09-27 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
WO2018096365A1 (en) 2016-11-27 2018-05-31 Bicyclerd Limited Methods for treating cancer
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
KR20230042153A (ko) 2016-12-23 2023-03-27 바이사이클티엑스 리미티드 Mt1-mmp에 대한 결합용 펩티드 리간드
CN110603261A (zh) 2016-12-23 2019-12-20 拜斯科阿迪有限公司 具有新型键结构的肽衍生物
EP3565638B8 (en) 2017-01-06 2024-04-10 BicycleRD Limited Bicycle conjugate for treating cancer
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
CN111032678A (zh) 2017-06-26 2020-04-17 拜西克尔德有限公司 具有可检测部分的双环肽配体和其用途
JP2020529427A (ja) 2017-08-04 2020-10-08 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
US20200283482A1 (en) 2017-08-14 2020-09-10 Bicyclerd Limited Bicyclic peptide ligand prr-a conjugates and uses thereof
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
EP3755725A1 (en) 2018-02-23 2020-12-30 BicycleTX Limited Multimeric bicyclic peptide ligands
JP7551500B2 (ja) 2018-04-04 2024-09-17 バイスクルテクス・リミテッド ヘテロタンデム二環式ペプチド複合体
GB201808835D0 (en) 2018-05-30 2018-07-11 Bicyclerd Ltd Ligands and methods of selecting binding targets for such
GB201810320D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810329D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
GB201810327D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US10919937B2 (en) 2018-10-23 2021-02-16 Bicycletx Limited Bicyclic peptide ligands and uses thereof
GB201820325D0 (en) * 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
BR112021011340A2 (pt) 2018-12-13 2021-09-08 Bicycletx Limited Ligantes de peptídeo bicíclico específicos para mt1-mmp
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820320D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
JP2022514687A (ja) 2018-12-21 2022-02-14 バイスクルアールディー・リミテッド Pd-l1に特異的な二環式ペプチドリガンド
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
GB201900528D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2020178574A1 (en) 2019-03-04 2020-09-10 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
TW202110485A (zh) 2019-07-30 2021-03-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
US20220275053A1 (en) 2019-08-13 2022-09-01 Bicycletx Limited Modified multimeric bicyclic peptide ligands
GB201912320D0 (en) 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
GB201914233D0 (en) 2019-10-02 2019-11-13 Bicyclerd Ltd Phage cyclisation assay
EP4038096A1 (en) 2019-10-03 2022-08-10 BicycleTX Limited Heterotandem bicyclic peptide complexes
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
GB201918557D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201918559D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
JP2023506083A (ja) 2019-12-16 2023-02-14 バイスクルテクス・リミテッド Il-17に特異的な二環式ペプチドリガンド
GB201918558D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB202002706D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Pbp3 binding bicyclic peptide ligands
GB202002705D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Anti-infective bicyclic peptide conjugates
EP4132481A1 (en) 2020-04-06 2023-02-15 BicycleTX Limited Bicyclic peptide ligands specific for tslp
WO2021220011A1 (en) 2020-05-01 2021-11-04 Bicycletx Limited Anti-infective bicyclic peptide conjugates
WO2021229238A1 (en) 2020-05-15 2021-11-18 Bicycletx Limited Anti-infective bicyclic peptide ligands
GB202016331D0 (en) 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
AU2022205795A1 (en) 2021-01-08 2023-08-24 Bicycletx Limited Anti-infective bicyclic peptide ligands
EP4274837A1 (en) 2021-01-08 2023-11-15 BicycleTx Limited Anti-infective bicyclic peptide ligands
CN117120459A (zh) 2021-01-08 2023-11-24 拜斯科技术开发有限公司 抗感染双环肽配体
CA3206529A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Heterotandem bicyclic peptide complexes
EP4274839A1 (en) 2021-01-08 2023-11-15 BicycleTx Limited Anti-infective bicyclic peptide ligands
EP4274841A1 (en) 2021-01-08 2023-11-15 BicycleTx Limited Anti-infective bicyclic peptide ligands
TW202241488A (zh) 2021-01-11 2022-11-01 英商拜斯科技技術開發有限公司 治療癌症之方法
WO2023031623A2 (en) 2021-09-03 2023-03-09 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
GB202114282D0 (en) 2021-10-06 2021-11-17 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
GB202114279D0 (en) 2021-10-06 2021-11-17 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
GB202116266D0 (en) 2021-11-11 2021-12-29 Bicycletx Ltd Novel use
WO2023139292A1 (en) 2022-01-24 2023-07-27 Cambridge Enterprise Limited Tau therapy
WO2024009108A1 (en) 2022-07-07 2024-01-11 Bicycletx Limited Anti-infective bicyclic peptide ligands
WO2024184661A1 (en) 2023-03-09 2024-09-12 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047042A1 (en) 1990-07-19 1992-01-20 John Hannah Cyclic hiv principal neutralizing determinant peptides
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
FR2839452A1 (fr) 2002-05-07 2003-11-14 Pf Medicament Utilisation de peptide derive de la sous-unite beta de l'hcg pour generer une reponse de type ctl antitumorale
GB0213878D0 (en) 2002-06-17 2002-07-31 Protherics Plc Use
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound

Also Published As

Publication number Publication date
US20080313749A1 (en) 2008-12-18
AU2006206848A1 (en) 2006-07-27
WO2006078161A1 (en) 2006-07-27
CA2595902A1 (en) 2006-07-27
NZ560504A (en) 2009-07-31
AU2006206848B2 (en) 2012-05-31
ES2428869T3 (es) 2013-11-12
EP1844337B1 (en) 2013-07-03
CY1114441T1 (el) 2016-08-31
DK1844337T3 (da) 2013-09-30
US7863239B2 (en) 2011-01-04
SI1844337T1 (sl) 2013-11-29
JP5372380B2 (ja) 2013-12-18
EP1844337A1 (en) 2007-10-17
PL1844337T3 (pl) 2013-12-31
JP2008529482A (ja) 2008-08-07
CA2595902C (en) 2017-08-22

Similar Documents

Publication Publication Date Title
PT1844337E (pt) Compostos ligantes, compostos imunogénicos e peptidomiméticos
EP1930012A4 (en) COMPOSITION CONTAINING A CELLO-OLIGOSACCHARIDE
EP1962852A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1865042A4 (en) ANTI-FREEZE COMPOSITION
GB0508250D0 (en) Composition
GB0506044D0 (en) Composition
EP1847249A4 (en) hair dye
GB0507167D0 (en) Composition
EP1947129A4 (en) PHOTORADIC AND PHOTOCYSTIC CURING COMPOSITION
EP1864573A4 (en) AGRICULTURAL CHEMICAL COMPOSITION
GB0520523D0 (en) Object binding
EP1932681A4 (en) BINDER
GB0502341D0 (en) Composition
GB2424448B (en) Keep
GB2427979B (en) Radiotelephones
GB0506496D0 (en) Compound, composition and use
GB0513641D0 (en) Anti-egeing composition
GB2444005B (en) Compound, composition and use
GB0510286D0 (en) Composition
GB0519669D0 (en) Visors
GB2422575B (en) Files
GB0501646D0 (en) File
GB0515761D0 (en) Compound, composition and use
GB0520690D0 (en) Compound, composition and use
GB0506495D0 (en) Compound, composition and use